American Analyst Updates: Nov 5th, 2026

Analyst Ratings (USA)

Wall Street analyst outlook fot today remains mixed and increasingly cautious, with significant downgrades across technology, software, financial services, consumer discretionary, and industrial sectors, offset by selective upgrades in renewable energy, healthcare, transportation, and infrastructure. Technology stocks faced particular pressure, with multiple downgrades in enterprise software, financial technology, and digital advertising reflecting concerns over valuations, slowing growth, and competitive pressures. Semiconductor analysts also showed greater caution, although artificial intelligence infrastructure continues to attract favourable coverage and new Buy recommendations. Consumer-related businesses experienced weaker sentiment amid concerns over spending trends and earnings expectations, while renewable energy, medical technology, and select transportation companies benefited from improving analyst confidence.

Updates (734)

3M (MMM) — Goldman Sachs maintains its Buy rating and raises its price target to $225.00 from $200.00.

Aardvark Therapeutics (AARD) — Raymond James downgrades its rating from Strong Buy to Market Perform.

Acadia Healthcare (ACHC) — Barclays maintains its Equal Weight rating and raises its price target to $35.00 from $32.00.

ACADIA Pharmaceuticals (ACAD) — RBC Capital Markets maintains its Outperform rating and raises its price target to $38.00 from $36.00.

Acadian Asset Management (AAMI) — Morgan Stanley upgrades its rating from Equal Weight to Overweight and raises its price target to $110.00 from $97.00.

AdaptHealth (AHCO) — Leerink Partners maintains its Outperform rating and raises its price target to $8.00 from $7.00.

Addus HomeCare (ADUS) — TD Cowen maintains its Buy rating and raises its price target to $145.00 from $131.00.

Addus HomeCare (ADUS) — Truist maintains its Buy rating and raises its price target to $148.00 from $135.00.

Addus HomeCare (ADUS) — UBS maintains its Buy rating and raises its price target to $160.00 from $145.00.

Adient (ADNT) — JPMorgan maintains its Overweight rating and lowers its price target to $23.00 from $25.00.

ADMA Biologics (ADMA) — Cantor Fitzgerald maintains its Neutral rating and raises its price target to $13.00 from $12.00.

ADMA Biologics (ADMA) — Mizuho sets a price target of $18.00.

Advanced Micro Devices (AMD) — HSBC maintains its Hold rating with a price target of $540.00.

Afya (AFYA) — Morgan Stanley upgrades its rating from Underweight to Equal Weight with a price target of $12.60.

Allegiant Travel (ALGT) — Raymond James maintains its Strong-Buy rating with a price target of $120.00.

Allstate (ALL) — Barclays maintains its Underweight rating and raises its price target to $228.00 from $221.00.

Amcor (AMCR) — Deutsche Bank downgrades its rating from Buy to Hold.

Amcor (AMCR) — Truist maintains its Buy rating and raises its price target to $53.00 from $51.00.

American Bitcoin (ABTC) — BTIG Research maintains its Buy rating and lowers its price target to $12.00 from $15.00.

American Financial Group (AFG) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $180.00 from $166.00.

American International Group (AIG) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $85.00 from $83.00.

American Tower (AMT) — Argus maintains its Buy rating with a price target of $210.00.

American Water Works (AWK) — Huntington downgrades its rating from Outperform to Market Perform.

Amgen (AMGN) — Guggenheim maintains its Neutral rating and raises its price target to $435.00 from $378.00.

Amgen (AMGN) — Leerink Partners maintains its Market Perform rating and raises its price target to $464.00 from $395.00.

Amneal Pharmaceuticals (AMRX) — Leerink Partners maintains its Outperform rating and raises its price target to $25.00 from $23.00.

Amplitude (AMPL) — BTIG Research maintains its Buy rating and raises its price target to $19.00 from $17.00.

Amplitude (AMPL) — KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $22.00 from $14.00.

Amplitude (AMPL) — Needham & Company LLC maintains its Buy rating and raises its price target to $21.00 from $18.00.

Amplitude (AMPL) — Piper Sandler maintains its Overweight rating and raises its price target to $22.00 from $18.00.

Amplitude (AMPL) — UBS maintains its Buy rating and raises its price target to $22.00 from $13.00.

Amylyx Pharmaceuticals (AMLX) — Stifel sets a price target of $45.00.

Angel Oak Mortgage REIT (AOMR) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $8.00 from $10.00.

Angi (ANGI) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $7.00 from $5.00.

APA (APA) — Barclays maintains its Equal Weight rating and raises its price target to $44.00 from $40.00.

APA (APA) — Stephens maintains its Equal Weight rating and raises its price target to $51.00 from $49.00.

Appian (APPN) — William Blair upgrades its rating from Market Perform to Outperform.

AppLovin (APP) — BTIG Research maintains its Buy rating and raises its price target to $450.00 from $396.00.

AppLovin (APP) — Goldman Sachs maintains its Neutral rating and raises its price target to $445.00 from $400.00.

AppLovin (APP) — Needham & Company LLC maintains its Buy rating with a price target of $475.00.

AppLovin (APP) — Oppenheimer maintains its Outperform rating and raises its price target to $520.00 from $490.00.

AppLovin (APP) — Piper Sandler maintains its Neutral rating and raises its price target to $355.00 from $325.00.

AppLovin (APP) — RBC Capital Markets maintains its Outperform rating and raises its price target to $520.00 from $500.00.

AppLovin (APP) — Scotiabank maintains its Sector Outperform rating and lowers its price target to $450.00 from $515.00.

AppLovin (APP) — Wedbush maintains its Outperform rating and raises its price target to $600.00 from $560.00.

ArcBest (ARCB) — Citigroup maintains its Buy rating and raises its price target to $175.00 from $170.00.

ArcBest (ARCB) — JPMorgan maintains its Neutral rating and raises its price target to $164.00 from $158.00.

Arcus Biosciences (RCUS) — Leerink Partners maintains its Outperform rating and raises its price target to $49.00 from $46.00.

Arcus Biosciences (RCUS) — Truist maintains its Buy rating and lowers its price target to $40.00 from $41.00.

Arcus Biosciences (RCUS) — Wedbush maintains its Outperform rating and lowers its price target to $45.00 from $49.00.

Arcutis Biotherapeutics (ARQT) — Needham & Company LLC sets a price target of $40.00.

Arcutis Biotherapeutics (ARQT) — TD Cowen maintains its Buy rating and raises its price target to $40.00 from $35.00.

ARM (ARM) — Barclays maintains its Overweight rating and lowers its price target to $325.00 from $360.00.

ARM (ARM) — Goldman Sachs maintains its Sell rating with a price target of $160.00.

ARM (ARM) — HSBC maintains its Hold rating with a price target of $215.00.

ARM (ARM) — JPMorgan maintains its Overweight rating and lowers its price target to $245.00 from $255.00.

ARM (ARM) — Needham & Company LLC maintains its Buy rating with a price target of $255.00.

ARM (ARM) — Piper Sandler maintains its Overweight rating and lowers its price target to $270.00 from $320.00.

ARM (ARM) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $300.00 from $340.00.

ARM (ARM) — TD Cowen maintains its Buy rating and lowers its price target to $250.00 from $350.00.

ARM (ARM) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $255.00 from $280.00.

Ashland (ASH) — JPMorgan maintains its Overweight rating and raises its price target to $82.00 from $80.00.

Assurant (AIZ) — Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $345.00 from $325.00.

Astera Labs (ALAB) — BMO Capital Markets initiates coverage with a Outperform rating and a price target of $375.00.

ATI Inc. (ATI) — Citigroup initiates coverage with a Buy rating and a price target of $229.00.

Avient (AVNT) — Barclays maintains its Equal Weight rating and raises its price target to $50.00 from $44.00.

Avient (AVNT) — Truist maintains its Buy rating and raises its price target to $56.00 from $50.00.

Avis Budget Group (CAR) — Goldman Sachs maintains its Sell rating and raises its price target to $108.00 from $94.00.

Avis Budget Group (CAR) — JPMorgan maintains its Underweight rating and lowers its price target to $85.00 from $105.00.

Avnet (AVT) — Truist maintains its Buy rating and raises its price target to $125.00 from $110.00.

Avnet (AVT) — Wells Fargo & Company maintains its Underweight rating and raises its price target to $85.00 from $80.00.

Ball (BALL) — Citigroup maintains its Buy rating and raises its price target to $77.00 from $75.00.

Ball (BALL) — RBC Capital Markets maintains its Outperform rating and raises its price target to $77.00 from $73.00.

Beam Therapeutics (BEAM) — Guggenheim maintains its Buy rating and lowers its price target to $51.00 from $55.00.

Becton, Dickinson and Company (BDX) — Jefferies Financial Group maintains its Buy rating with a price target of $242.00.

BeOne Medicines (ONC) — Jefferies Financial Group maintains its Buy rating with a price target of $470.00.

Beyond Meat (BYND) — Barclays maintains its Underweight rating and lowers its price target to $5.00 from $10.00.

Billiontoone (BLLN) — BTIG Research maintains its Buy rating with a price target of $130.00.

Billiontoone (BLLN) — JPMorgan maintains its Overweight rating and raises its price target to $135.00 from $130.00.

Bio-Rad Laboratories (BIO) — RBC Capital Markets maintains its Outperform rating and raises its price target to $440.00 from $390.00.

BioCryst Pharmaceuticals (BCRX) — Wedbush maintains its Outperform rating and lowers its price target to $17.00 from $18.00.

Block (XYZ) — Argus maintains its Buy rating and raises its price target to $105.00 from $103.00.

Block (XYZ) — Barclays maintains its Overweight rating and raises its price target to $105.00 from $100.00.

Block (XYZ) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $110.00 from $97.00.

Boise Cascade (BCC) — BMO Capital Markets downgrades its rating from Outperform to Market Perform and lowers its price target to $88.00 from $100.00.

Brilliant Earth Group (BRLT) — Jefferies Financial Group maintains its Hold rating with a price target of $1.40.

Bristow Group (VTOL) — Raymond James maintains its Outperform rating with a price target of $63.00.

Brookfield Asset Management (BAM) — JPMorgan maintains its Neutral rating and raises its price target to $58.00 from $55.00.

Brookfield Renewable Partners (BEP) — Desjardins upgrades its rating from Hold to Buy.

Bruker (BRKR) — Citigroup maintains its Neutral rating and raises its price target to $64.00 from $53.00.

Bruker (BRKR) — Leerink Partners maintains its Outperform rating and raises its price target to $85.00 from $80.00.

Cardinal Health (CAH) — Mizuho sets a price target of $290.00.

Caris Life Sciences (CAI) — BTIG Research maintains its Buy rating with a price target of $38.00.

Caris Life Sciences (CAI) — TD Cowen maintains its Buy rating and raises its price target to $38.00 from $36.00.

Caris Life Sciences (CAI) — UBS sets a price target of $38.00.

Cars.com (CARS) — BTIG Research maintains its Buy rating and raises its price target to $16.00 from $14.00.

CAVA Group (CAVA) — BNP Paribas Exane maintains its Neutral rating and lowers its price target to $62.00 from $84.00.

CAVA Group (CAVA) — KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $75.00 from $80.00.

CAVA Group (CAVA) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $80.00 from $85.00.

CAVA Group (CAVA) — Sanford C. Bernstein maintains its Outperform rating and lowers its price target to $80.00 from $95.00.

CAVA Group (CAVA) — TD Cowen maintains its Buy rating and lowers its price target to $76.00 from $78.00.

CAVA Group (CAVA) — Telsey Advisory Group sets a price target of $76.00.

CDW (CDW) — Citigroup maintains its Neutral rating and raises its price target to $170.00 from $150.00.

CDW (CDW) — JPMorgan maintains its Overweight rating and raises its price target to $195.00 from $170.00.

CDW (CDW) — UBS maintains its Buy rating and raises its price target to $195.00 from $159.00.

Celanese (CE) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $60.00 from $65.00.

Cencora (COR) — Leerink Partners maintains its Outperform rating and raises its price target to $405.00 from $388.00.

Ceragon Networks (CRNT) — Needham & Company LLC maintains its Buy rating and raises its price target to $3.50 from $3.00.

Champion Homes (SKY) — Barclays maintains its Overweight rating and raises its price target to $110.00 from $109.00.

Champion Homes (SKY) — RBC Capital Markets maintains its Outperform rating and raises its price target to $99.00 from $94.00.

Charles River Laboratories International (CRL) — Barclays maintains its Overweight rating and raises its price target to $375.00 from $330.00.

Charles River Laboratories International (CRL) — RBC Capital Markets maintains its Outperform rating and raises its price target to $352.00 from $322.00.

Charles River Laboratories International (CRL) — UBS maintains its Buy rating and raises its price target to $387.00 from $357.00.

Chatham Lodging Trust (CLDT) — Stifel sets a price target of $16.50.

Chime Financial (CHYM) — Goldman Sachs maintains its Buy rating and raises its price target to $43.00 from $38.00.

Chime Financial (CHYM) — JPMorgan maintains its Overweight rating and raises its price target to $40.00 from $35.00.

Chime Financial (CHYM) — Scotiabank maintains its Sector Outperform rating and raises its price target to $44.00 from $42.00.

Chime Financial (CHYM) — UBS maintains its Neutral rating and raises its price target to $34.00 from $31.00.

Chime Financial (CHYM) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $42.00 from $39.00.

Choice Hotels International (CHH) — Wedbush sets a price target of $130.00.

Cinemark (CNK) — Morgan Stanley upgrades its rating from Equal Weight to Overweight with a price target of $50.00.

Circle Internet Group (CRCL) — Citigroup initiates coverage with a Buy rating.

Circle Internet Group (CRCL) — Compass Point upgrades its rating from Neutral to Buy with a price target of $99.00.

Circle Internet Group (CRCL) — Deutsche Bank upgrades its rating from Hold to Buy.

Circle Internet Group (CRCL) — HC Wainwright maintains its Buy rating and lowers its price target to $100.00 from $104.00.

Circle Internet Group (CRCL) — JPMorgan maintains its Overweight rating and lowers its price target to $100.00 from $110.00.

Circle Internet Group (CRCL) — Keefe, Bruyette & Woods maintains its Market Perform rating and lowers its price target to $90.00 from $105.00.

Circle Internet Group (CRCL) — Mizuho sets a price target of $46.00.

Circle Internet Group (CRCL) — Morgan Stanley downgrades its rating from Underweight to Cautious.

Circle Internet Group (CRCL) — Needham & Company LLC maintains its Buy rating and lowers its price target to $103.00 from $134.00.

Circle Internet Group (CRCL) — Susquehanna maintains its Neutral rating and lowers its price target to $86.00 from $92.00.

Circle Internet Group (CRCL) — TD Cowen maintains its Buy rating and lowers its price target to $87.00 from $92.00.

Circle Internet Group (CRCL) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $101.00 from $115.00.

Cisco (CSCO) — Morgan Stanley downgrades its rating from Overweight to Equal Weight and lowers its price target to $120.00 from $135.00.

Clarivate (CLVT) — Goldman Sachs maintains its Neutral rating and lowers its price target to $2.30 from $2.60.

Clarivate (CLVT) — Jefferies Financial Group maintains its Hold rating with a price target of $2.25.

CLEAR Secure (YOU) — JPMorgan maintains its Overweight rating and raises its price target to $75.00 from $55.00.

CLEAR Secure (YOU) — Wells Fargo & Company maintains its Underweight rating and raises its price target to $50.00 from $45.00.

Climb Bio (CLYM) — Wedbush maintains its Outperform rating with a price target of $27.00.

Clover Health Investments (CLOV) — UBS maintains its Neutral rating and raises its price target to $5.50 from $5.00.

Coca-Cola Europacific Partners (CCEP) — Barclays maintains its Overweight rating and raises its price target to $124.00 from $112.00.

Collegium Pharmaceutical (COLL) — Needham & Company LLC maintains its Buy rating and lowers its price target to $44.00 from $46.00.

Colliers International Group (CIGI) — National Bank Financial maintains its Outperform rating and raises its price target to $122.00 from $109.00.

Colliers International Group (CIGI) — Raymond James maintains its Strong-Buy rating and lowers its price target to $150.00 from $160.00.

Colliers International Group (CIGI) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $140.00 from $155.00.

Colliers International Group (CIGI) — Stifel maintains its Buy rating and lowers its price target to $150.00 from $155.00.

Community Healthcare Trust (CHCT) — Piper Sandler maintains its Neutral rating and raises its price target to $16.00 from $14.00.

ConocoPhillips (COP) — Mizuho sets a price target of $149.00.

Core Natural Resources (CNR) — Jefferies Financial Group maintains its Buy rating with a price target of $100.00.

Corning (GLW) — Fox Advisors upgrades its rating from Equal Weight to Overweight.

Corpay (CPAY) — JPMorgan maintains its Overweight rating and raises its price target to $500.00 from $470.00.

Corpay (CPAY) — Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $525.00 from $470.00.

Corpay (CPAY) — Oppenheimer maintains its Outperform rating and raises its price target to $461.00 from $454.00.

Corpay (CPAY) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $474.00 from $438.00.

Corpay (CPAY) — Scotiabank maintains its Sector Outperform rating and raises its price target to $539.00 from $536.00.

Corpay (CPAY) — UBS maintains its Neutral rating and raises its price target to $465.00 from $415.00.

Costco Wholesale (COST) — JPMorgan maintains its Overweight rating and raises its price target to $1,150.00 from $1,015.00.

Coupang (CPNG) — Barclays maintains its Overweight rating and raises its price target to $32.00 from $29.00.

Coupang (CPNG) — Sanford C. Bernstein maintains its Underperform rating and lowers its price target to $11.00 from $12.00.

Cricut (CRCT) — Barclays maintains its Underweight rating and raises its price target to $6.00 from $4.00.

Criteo (CRTO) — Citigroup maintains its Buy rating and lowers its price target to $21.00 from $23.00.

Criteo (CRTO) — Wedbush maintains its Outperform rating and lowers its price target to $21.00 from $25.00.

Criteo (CRTO) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $14.00 from $15.00.

CVS Health (CVS) — Barclays maintains its Overweight rating and lowers its price target to $107.00 from $108.00.

CVS Health (CVS) — Leerink Partners maintains its Outperform rating and lowers its price target to $104.00 from $112.00.

Cytokinetics (CYTK) — Citigroup maintains its Buy rating and raises its price target to $105.00 from $99.00.

Cytokinetics (CYTK) — Leerink Partners maintains its Outperform rating and lowers its price target to $100.00 from $103.00.

Datadog (DDOG) — Barclays maintains its Overweight rating and lowers its price target to $262.00 from $300.00.

Datadog (DDOG) — Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $260.00 from $327.00.

Datadog (DDOG) — Citigroup maintains its Buy rating and lowers its price target to $290.00 from $305.00.

Datadog (DDOG) — DA Davidson maintains its Buy rating and lowers its price target to $275.00 from $315.00.

Datadog (DDOG) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $270.00 from $320.00.

Datadog (DDOG) — Rosenblatt Securities maintains its Buy rating and lowers its price target to $285.00 from $305.00.

Datadog (DDOG) — Sanford C. Bernstein maintains its Outperform rating and lowers its price target to $273.00 from $350.00.

Datadog (DDOG) — Scotiabank maintains its Sector Outperform rating and lowers its price target to $260.00 from $285.00.

Datadog (DDOG) — TD Cowen maintains its Buy rating and lowers its price target to $275.00 from $300.00.

Datadog (DDOG) — Wedbush maintains its Outperform rating and lowers its price target to $240.00 from $275.00.

Datadog (DDOG) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $300.00 from $325.00.

Dave (DAVE) — JPMorgan maintains its Overweight rating and lowers its price target to $435.00 from $480.00.

Deckers Outdoor (DECK) — Argus maintains its Buy rating and lowers its price target to $102.00 from $128.00.

Design Therapeutics (DSGN) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $19.00 from $20.00.

Dianthus Therapeutics (DNTH) — Raymond James maintains its Strong-Buy rating with a price target of $134.00.

DigitalOcean (DOCN) — Goldman Sachs maintains its Buy rating and lowers its price target to $156.00 from $178.00.

Dollar Tree (DLTR) — Loop Capital downgrades its rating from Buy to Hold with a price target of $140.00.

Duolingo (DUOL) — Bank of America maintains its Underperform rating with a price target of $108.00.

Duolingo (DUOL) — Truist maintains its Hold rating and raises its price target to $170.00 from $120.00.

DuPont de Nemours (DD) — RBC Capital Markets maintains its Outperform rating and raises its price target to $173.00 from $160.00.

DuPont de Nemours (DD) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $170.00 from $166.00.

Dutch Bros (BROS) — BNP Paribas Exane maintains its Outperform rating and lowers its price target to $54.00 from $77.00.

Dutch Bros (BROS) — KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $52.00 from $59.00.

Dutch Bros (BROS) — Mizuho sets a price target of $55.00.

Dutch Bros (BROS) — Oppenheimer maintains its Outperform rating and lowers its price target to $54.00 from $66.00.

Dutch Bros (BROS) — RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $38.00 from $46.00.

Dutch Bros (BROS) — Stephens maintains its Overweight rating and lowers its price target to $47.00 from $65.00.

Dutch Bros (BROS) — TD Cowen maintains its Buy rating and lowers its price target to $50.00 from $55.00.

Dutch Bros (BROS) — Telsey Advisory Group sets a price target of $56.00.

Dutch Bros (BROS) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $50.00 from $55.00.

e.l.f. Beauty (ELF) — Citigroup maintains its Buy rating and raises its price target to $139.00 from $130.00.

e.l.f. Beauty (ELF) — JPMorgan maintains its Overweight rating and raises its price target to $135.00 from $130.00.

e.l.f. Beauty (ELF) — Piper Sandler maintains its Neutral rating and raises its price target to $110.00 from $100.00.

e.l.f. Beauty (ELF) — Raymond James maintains its Strong-Buy rating with a price target of $132.00.

e.l.f. Beauty (ELF) — UBS maintains its Neutral rating and raises its price target to $129.00 from $116.00.

Eagle Materials (EXP) — DA Davidson sets a price target of $195.00.

Eagle Materials (EXP) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $189.00 from $188.00.

eBay (EBAY) — Argus maintains its Buy rating and raises its price target to $138.00 from $133.00.

Edgewise Therapeutics (EWTX) — Raymond James maintains its Underperform rating with a price target of $85.00.

Edgewise Therapeutics (EWTX) — Wedbush maintains its Outperform rating and lowers its price target to $51.00 from $53.00.

Edwards Lifesciences (EW) — Barclays maintains its Overweight rating and raises its price target to $120.00 from $110.00.

Edwards Lifesciences (EW) — BTIG Research maintains its Buy rating and raises its price target to $115.00 from $110.00.

Edwards Lifesciences (EW) — Citigroup maintains its Buy rating and raises its price target to $117.00 from $110.00.

Edwards Lifesciences (EW) — JPMorgan maintains its Overweight rating and raises its price target to $120.00 from $105.00.

Edwards Lifesciences (EW) — Leerink Partners maintains its Outperform rating and raises its price target to $112.00 from $101.00.

Edwards Lifesciences (EW) — Mizuho sets a price target of $120.00.

Edwards Lifesciences (EW) — Piper Sandler maintains its Overweight rating and raises its price target to $115.00 from $101.00.

Edwards Lifesciences (EW) — RBC Capital Markets maintains its Outperform rating and raises its price target to $115.00 from $110.00.

Edwards Lifesciences (EW) — Robert W. Baird upgrades its rating from Neutral to Outperform with a price target of $116.00.

Edwards Lifesciences (EW) — Sanford C. Bernstein maintains its Market Perform rating and raises its price target to $106.00 from $99.00.

Edwards Lifesciences (EW) — UBS maintains its Buy rating and raises its price target to $118.00 from $110.00.

Edwards Lifesciences (EW) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $113.00 from $100.00.

Emerson Electric (EMR) — BNP Paribas Exane maintains its Outperform rating and raises its price target to $200.00 from $185.00.

Emerson Electric (EMR) — Citigroup maintains its Buy rating and raises its price target to $198.00 from $182.00.

Emerson Electric (EMR) — KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $200.00 from $170.00.

Emerson Electric (EMR) — RBC Capital Markets maintains its Outperform rating and raises its price target to $196.00 from $188.00.

Emerson Electric (EMR) — Sanford C. Bernstein maintains its Outperform rating and raises its price target to $196.00 from $186.00.

Emerson Electric (EMR) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $180.00 from $177.00.

Encore Capital Group (ECPG) — Citizens Jmp maintains its Market Outperform rating and raises its price target to $140.00 from $115.00.

Encore Capital Group (ECPG) — Truist maintains its Buy rating and raises its price target to $122.00 from $112.00.

Enovis (ENOV) — BTIG Research maintains its Buy rating and raises its price target to $42.00 from $36.00.

Enovis (ENOV) — Needham & Company LLC maintains its Buy rating and raises its price target to $38.00 from $34.00.

Envista (NVST) — UBS maintains its Neutral rating and raises its price target to $29.00 from $27.00.

EPAM Systems (EPAM) — Needham & Company LLC maintains its Overweight rating and lowers its price target to $29.00 from $31.00.

Everus Construction Group (ECG) — Oppenheimer maintains its Outperform rating and lowers its price target to $170.00 from $200.00.

Evolent Health (EVH) — Needham & Company LLC maintains its Buy rating and raises its price target to $6.00 from $5.00.

Evolus (EOLS) — BTIG Research maintains its Buy rating and raises its price target to $15.00 from $13.00.

Exelixis (EXEL) — Leerink Partners maintains its Market Perform rating and raises its price target to $58.00 from $55.00.

Expedia Group (EXPE) — Barclays maintains its Equal Weight rating and lowers its price target to $310.00 from $320.00.

Expedia Group (EXPE) — BTIG Research maintains its Buy rating with a price target of $400.00.

Expedia Group (EXPE) — Cantor Fitzgerald maintains its Neutral rating and raises its price target to $320.00 from $310.00.

Expedia Group (EXPE) — Goldman Sachs maintains its Buy rating with a price target of $320.00.

Expedia Group (EXPE) — JPMorgan maintains its Neutral rating and lowers its price target to $315.00 from $330.00.

Expedia Group (EXPE) — Piper Sandler maintains its Neutral rating and raises its price target to $335.00 from $325.00.

Expedia Group (EXPE) — Wedbush maintains its Outperform rating and lowers its price target to $384.00 from $417.00.

Expedia Group (EXPE) — Wells Fargo & Company maintains its Cautious rating and raises its price target to $278.00 from $275.00.

Expro Group (XPRO) — Barclays downgrades its rating from Overweight to Equal Weight and lowers its price target to $14.00 from $19.00.

FactSet Research Systems (FDS) — Wells Fargo & Company maintains its Underweight rating and raises its price target to $290.00 from $250.00.

Fair Isaac (FICO) — Barclays maintains its Overweight rating and lowers its price target to $800.00 from $875.00.

Fair Isaac (FICO) — JPMorgan maintains its Neutral rating and lowers its price target to $800.00 from $900.00.

Fair Isaac (FICO) — Needham & Company LLC maintains its Buy rating and lowers its price target to $925.00 from $1,100.00.

Fair Isaac (FICO) — RBC Capital Markets downgrades its rating from Outperform to Sector Perform and lowers its price target to $770.00 from $1,045.00.

Fair Isaac (FICO) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $650.00 from $735.00.

Fastly (FSLY) — Piper Sandler maintains its Neutral rating and lowers its price target to $24.00 from $28.00.

Fastly (FSLY) — Raymond James maintains its Outperform rating with a price target of $24.00.

Fastly (FSLY) — RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $19.00 from $25.00.

Fidelity National Information Services (FIS) — Bank of America downgrades its rating from Buy to Neutral and lowers its price target to $33.00 from $42.00.

Fidelity National Information Services (FIS) — Barclays maintains its Equal Weight rating and lowers its price target to $30.00 from $38.00.

Fidelity National Information Services (FIS) — Citigroup maintains its Neutral rating and lowers its price target to $30.00 from $39.00.

Fidelity National Information Services (FIS) — Goldman Sachs maintains its Buy rating and lowers its price target to $35.00 from $44.00.

Fidelity National Information Services (FIS) — Keefe, Bruyette & Woods maintains its Outperform rating and lowers its price target to $42.00 from $50.00.

Fidelity National Information Services (FIS) — National Bank Financial sets a price target of $46.00.

Fidelity National Information Services (FIS) — Piper Sandler maintains its Neutral rating and lowers its price target to $31.00 from $42.00.

Fidelity National Information Services (FIS) — RBC Capital Markets downgrades its rating from Outperform to Sector Perform and lowers its price target to $37.00 from $53.00.

Fidelity National Information Services (FIS) — Susquehanna maintains its Neutral rating and lowers its price target to $32.00 from $37.00.

Fidelity National Information Services (FIS) — TD Cowen maintains its Buy rating and lowers its price target to $38.00 from $47.00.

Fidelity National Information Services (FIS) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $33.00 from $46.00.

Figma (FIG) — JPMorgan maintains its Neutral rating and lowers its price target to $24.00 from $28.00.

Figma (FIG) — RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $24.00 from $28.00.

First Industrial Realty Trust (FR) — Truist maintains its Buy rating and lowers its price target to $62.00 from $73.00.

First Solar (FSLR) — William Blair upgrades its rating from Market Perform to Outperform.

Five Below (FIVE) — Truist maintains its Buy rating and raises its price target to $302.00 from $297.00.

Flutter Entertainment (FLUT) — Barclays maintains its Overweight rating and lowers its price target to $125.00 from $133.00.

Flutter Entertainment (FLUT) — Citizens Jmp maintains its Market Outperform rating and lowers its price target to $116.00 from $129.00.

Flutter Entertainment (FLUT) — Susquehanna maintains its Positive rating and raises its price target to $101.00 from $100.00.

Flutter Entertainment (FLUT) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $86.00 from $112.00.

Flywire (FLYW) — Citigroup maintains its Neutral rating and raises its price target to $23.00 from $19.00.

Freshpet (FRPT) — JPMorgan maintains its Overweight rating and raises its price target to $78.00 from $76.00.

Freshpet (FRPT) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $84.00 from $77.00.

Frontier Group Holdings (ULCC) — Deutsche Bank upgrades its rating from Hold to Buy and raises its price target to $10.00 from $7.00.

GATX (GATX) — Susquehanna maintains its Positive rating and raises its price target to $220.00 from $218.00.

Genius Sports (GENI) — BTIG Research maintains its Buy rating and lowers its price target to $8.00 from $10.00.

GlobalFoundries (GFS) — Citigroup maintains its Neutral rating and lowers its price target to $46.00 from $58.00.

GlobalFoundries (GFS) — JPMorgan maintains its Neutral rating and lowers its price target to $50.00 from $57.00.

GlobalFoundries (GFS) — Susquehanna maintains its Positive rating and lowers its price target to $110.00 from $125.00.

GlobalFoundries (GFS) — TD Cowen maintains its Buy rating and lowers its price target to $60.00 from $75.00.

GlobalFoundries (GFS) — Wedbush maintains its Neutral rating and lowers its price target to $45.00 from $72.00.

GRAIL (GRAL) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $100.00 from $84.00.

Grand Canyon Education (LOPE) — Truist maintains its Buy rating and lowers its price target to $180.00 from $200.00.

Greenbrier Companies (GBX) — Susquehanna maintains its Neutral rating and lowers its price target to $45.00 from $52.00.

Greif (GEF) — Truist maintains its Hold rating and lowers its price target to $88.00 from $94.00.

GXO Logistics (GXO) — Citigroup maintains its Buy rating and raises its price target to $66.00 from $65.00.

GXO Logistics (GXO) — Goldman Sachs maintains its Buy rating with a price target of $66.00.

GXO Logistics (GXO) — JPMorgan maintains its Overweight rating and raises its price target to $73.00 from $68.00.

GXO Logistics (GXO) — Oppenheimer maintains its Outperform rating and raises its price target to $65.00 from $61.00.

GXO Logistics (GXO) — UBS maintains its Buy rating and raises its price target to $69.00 from $64.00.

Haemonetics (HAE) — BTIG Research maintains its Buy rating and raises its price target to $142.00 from $130.00.

Haemonetics (HAE) — Mizuho sets a price target of $165.00.

Hamilton Lane (HLNE) — UBS maintains its Buy rating and raises its price target to $120.00 from $115.00.

HCI Group (HCI) — Citizens Jmp maintains its Market Outperform rating and raises its price target to $280.00 from $265.00.

HCI Group (HCI) — Truist maintains its Buy rating and raises its price target to $245.00 from $235.00.

Hillman Solutions (HLMN) — Barclays maintains its Equal Weight rating and lowers its price target to $10.00 from $11.00.

HubSpot (HUBS) — Barclays maintains its Equal Weight rating and lowers its price target to $222.00 from $240.00.

HubSpot (HUBS) — BTIG Research downgrades its rating from Buy to Neutral.

HubSpot (HUBS) — Cantor Fitzgerald downgrades its rating from Neutral to Underweight and lowers its price target to $170.00 from $265.00.

HubSpot (HUBS) — JPMorgan maintains its Neutral rating and lowers its price target to $224.00 from $240.00.

HubSpot (HUBS) — KeyBanc Capital Markets downgrades its rating from Overweight to Sector Weight.

HubSpot (HUBS) — Morgan Stanley downgrades its rating from Overweight to Equal Weight with a price target of $229.00.

HubSpot (HUBS) — Piper Sandler maintains its Neutral rating and lowers its price target to $200.00 from $220.00.

HubSpot (HUBS) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $260.00 from $300.00.

HubSpot (HUBS) — TD Cowen maintains its Hold rating and lowers its price target to $215.00 from $260.00.

HubSpot (HUBS) — Truist maintains its Buy rating and lowers its price target to $230.00 from $275.00.

HubSpot (HUBS) — UBS downgrades its rating from Neutral to Underweight with a price target of $170.00.

HubSpot (HUBS) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $200.00 from $250.00.

Huntington Bancshares (HBAN) — Argus maintains its Buy rating and lowers its price target to $18.00 from $20.00.

Hut 8 (HUT) — Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $127.00 from $151.00.

Hut 8 (HUT) — Needham & Company LLC maintains its Buy rating and lowers its price target to $101.00 from $138.00.

Hut 8 (HUT) — Rosenblatt Securities maintains its Buy rating and lowers its price target to $100.00 from $124.00.

Hut 8 (HUT) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $148.00 from $175.00.

IDEAYA Biosciences (IDYA) — Citigroup maintains its Buy rating and raises its price target to $66.00 from $65.00.

Incyte (INCY) — Leerink Partners maintains its Outperform rating and lowers its price target to $150.00 from $154.00.

Innoviva (INVA) — Oppenheimer maintains its Outperform rating and lowers its price target to $34.00 from $35.00.

Insulet (PODD) — Citigroup maintains its Neutral rating and raises its price target to $170.00 from $150.00.

Insulet (PODD) — JPMorgan maintains its Neutral rating and raises its price target to $170.00 from $152.00.

Insulet (PODD) — Leerink Partners maintains its Market Perform rating and raises its price target to $167.00 from $143.00.

Insulet (PODD) — RBC Capital Markets maintains its Outperform rating and raises its price target to $180.00 from $160.00.

Insulet (PODD) — Sanford C. Bernstein maintains its Outperform rating and raises its price target to $200.00 from $175.00.

Insulet (PODD) — UBS maintains its Neutral rating and raises its price target to $171.00 from $150.00.

Insulet (PODD) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $172.00 from $144.00.

International Flavors & Fragrances (IFF) — Citigroup maintains its Buy rating and raises its price target to $105.00 from $100.00.

International Flavors & Fragrances (IFF) — JPMorgan maintains its Overweight rating and raises its price target to $95.00 from $92.00.

International Flavors & Fragrances (IFF) — UBS maintains its Neutral rating and raises its price target to $95.00 from $91.00.

Inventiva (IVA) — HC Wainwright maintains its Buy rating with a price target of $14.00.

IPG Photonics (IPGP) — Sanford C. Bernstein maintains its Outperform rating with a price target of $92.00.

Jack Henry & Associates (JKHY) — Barclays maintains its Overweight rating and raises its price target to $190.00 from $185.00.

Jack Henry & Associates (JKHY) — Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $215.00 from $200.00.

Jack Henry & Associates (JKHY) — RBC Capital Markets maintains its Outperform rating and raises its price target to $195.00 from $178.00.

Jack Henry & Associates (JKHY) — UBS maintains its Neutral rating and raises its price target to $185.00 from $170.00.

JELD-WEN (JELD) — Barclays maintains its Equal Weight rating and lowers its price target to $1.50 from $2.00.

JetBlue Airways (JBLU) — Deutsche Bank upgrades its rating from Hold to Buy and raises its price target to $5.50 from $3.00.

Joby Aviation (JOBY) — Canaccord Genuity upgrades its rating from Hold to Buy with a price target of $7.00.

Joby Aviation (JOBY) — Canaccord Genuity Group upgrades its rating from Hold to Buy and lowers its price target to $7.00 from $11.50.

Joby Aviation (JOBY) — Needham & Company LLC maintains its Buy rating and lowers its price target to $10.00 from $15.00.

Keel Infrastructure (KEEL) — HC Wainwright maintains its Buy rating and lowers its price target to $3.25 from $4.00.

Kennametal (KMT) — JPMorgan maintains its Underweight rating and lowers its price target to $27.00 from $30.00.

Keurig Dr Pepper (KDP) — Barclays maintains its Overweight rating and raises its price target to $41.00 from $38.00.

Klaviyo (KVYO) — Barclays maintains its Overweight rating and raises its price target to $23.00 from $22.00.

Klaviyo (KVYO) — Goldman Sachs maintains its Neutral rating with a price target of $22.50.

Klaviyo (KVYO) — Mizuho sets a price target of $24.00.

Knife River (KNF) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $59.00 from $58.00.

Knife River (KNF) — Stephens maintains its Overweight rating and raises its price target to $70.00 from $65.00.

Kraft Heinz (KHC) — UBS maintains its Neutral rating and raises its price target to $26.00 from $24.00.

Kraft Heinz (KHC) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $24.00 from $23.00.

Kyndryl (KD) — Scotiabank maintains its Sector Perform rating and raises its price target to $19.00 from $15.00.

Kyndryl (KD) — Susquehanna maintains its Neutral rating and raises its price target to $16.00 from $13.00.

Labcorp (LH) — HSBC upgrades its rating from Hold to Buy with a price target of $410.00.

Labcorp Holdings (LH) — HSBC Securities upgrades its rating from Hold to Buy with a price target of $410.00.

LegalZoom.com (LZ) — Bank of America downgrades its rating from Buy to Underperform.

LegalZoom.com (LZ) — JPMorgan maintains its Neutral rating and lowers its price target to $6.00 from $7.00.

LeMaitre Vascular (LMAT) — Citizens Jmp maintains its Market Outperform rating and lowers its price target to $110.00 from $127.00.

LeMaitre Vascular (LMAT) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $86.00 from $94.00.

LENZ Therapeutics (LENZ) — Citigroup maintains its Buy rating and lowers its price target to $9.00 from $10.00.

LifeStance Health Group (LFST) — BTIG Research maintains its Buy rating and raises its price target to $20.00 from $18.00.

Ligand Pharmaceuticals (LGND) — Citigroup maintains its Buy rating and raises its price target to $402.00 from $397.00.

Light & Wonder (LNWO) — JPMorgan downgrades its rating from Overweight to Neutral.

Limbach (LMB) — JPMorgan maintains its Underweight rating and raises its price target to $55.00 from $50.00.

LivaNova (LIVN) — Robert W. Baird maintains its Outperform rating and raises its price target to $111.00 from $95.00.

Lumen Technologies (LUMN) — Goldman Sachs maintains its Strong-Buy rating with a price target of $18.00.

Lumen Technologies (LUMN) — JPMorgan maintains its Neutral rating and lowers its price target to $6.00 from $7.00.

Lumen Technologies (LUMN) — TD Cowen maintains its Hold rating and lowers its price target to $8.00 from $9.00.

Lumen Technologies (LUMN) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $5.00 from $7.50.

Lyntris Inc. (LYNX) — Raymond James upgrades its rating from Outperform to Strong Buy with a price target of $18.00.

Lyntris Inc. (LYNX) — Robert W. Baird upgrades its rating from Neutral to Outperform with a price target of $18.00.

MACOM Technology Solutions (MTSI) — Needham & Company LLC maintains its Buy rating and lowers its price target to $300.00 from $410.00.

MACOM Technology Solutions (MTSI) — Stifel sets a price target of $360.00.

MACOM Technology Solutions (MTSI) — Susquehanna maintains its Neutral rating with a price target of $220.00.

Madison Square Garden Entertainment (MSGE) — JPMorgan maintains its Neutral rating and raises its price target to $84.00 from $83.00.

Madison Square Garden Entertainment (MSGE) — Susquehanna maintains its Positive rating and raises its price target to $93.00 from $92.00.

Magnite (MGNI) — RBC Capital Markets maintains its Outperform rating and raises its price target to $30.00 from $27.00.

Magnite (MGNI) — Scotiabank maintains its Sector Outperform rating and raises its price target to $30.00 from $27.00.

Magnite (MGNI) — Susquehanna maintains its Positive rating and raises its price target to $35.00 from $30.00.

Magnite (MGNI) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $23.00 from $22.00.

Manitowoc (MTW) — Wells Fargo & Company maintains its Underweight rating and raises its price target to $15.00 from $12.00.

Marathon Petroleum (MPC) — Piper Sandler maintains its Overweight rating and raises its price target to $466.00 from $462.00.

Marqeta (MQ) — UBS maintains its Neutral rating and raises its price target to $21.00 from $19.00.

Marriott Vacations Worldwide (VAC) — Barclays maintains its Overweight rating and lowers its price target to $139.00 from $140.00.

Marriott Vacations Worldwide (VAC) — JPMorgan maintains its Overweight rating and lowers its price target to $124.00 from $125.00.

Marriott Vacations Worldwide (VAC) — Wells Fargo & Company maintains its Underweight rating and lowers its price target to $97.00 from $100.00.

Martin Marietta Materials (MLM) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $589.00 from $579.00.

Masco (MAS) — Argus maintains its Buy rating and raises its price target to $95.00 from $92.00.

Mastercard (MA) — Truist maintains its Buy rating and raises its price target to $735.00 from $674.00.

Mastercard (MA) — UBS maintains its Buy rating with a price target of $725.00.

Matador Resources (MTDR) — Truist maintains its Buy rating and raises its price target to $66.00 from $65.00.

Materion (MTRN) — KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $232.00 from $306.00.

Materion (MTRN) — Seaport Research Partners upgrades its rating from Neutral to Buy with a price target of $250.00.

Matson (MATX) — Stephens maintains its Overweight rating and raises its price target to $300.00 from $270.00.

Mayville Engineering (MEC) — Citigroup maintains its Buy rating and lowers its price target to $27.00 from $38.00.

McDonald’s (MCD) — BTIG Research maintains its Buy rating and raises its price target to $305.00 from $295.00.

McDonald’s (MCD) — Citigroup maintains its Buy rating and raises its price target to $315.00 from $295.00.

McDonald’s (MCD) — JPMorgan maintains its Overweight rating and raises its price target to $270.00 from $250.00.

McDonald’s (MCD) — KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $307.00 from $280.00.

McDonald’s (MCD) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $300.00 from $285.00.

McDonald’s (MCD) — Sanford C. Bernstein maintains its Market Perform rating and raises its price target to $280.00 from $250.00.

McDonald’s (MCD) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $300.00 from $270.00.

McKesson (MCK) — Leerink Partners maintains its Outperform rating and raises its price target to $1,200.00 from $1,070.00.

McKesson (MCK) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $965.00 from $845.00.

McKesson (MCK) — TD Cowen maintains its Buy rating and raises its price target to $1,200.00 from $1,006.00.

Mechanics Bancorp (MCHB) — Keefe, Bruyette & Woods maintains its Market Perform rating and lowers its price target to $15.50 from $16.00.

Medline (MDLN) — BTIG Research maintains its Buy rating with a price target of $55.00.

Medline (MDLN) — Citigroup maintains its Buy rating and raises its price target to $47.00 from $45.00.

Medline (MDLN) — Leerink Partners maintains its Outperform rating and raises its price target to $46.00 from $43.00.

Medline (MDLN) — UBS maintains its Buy rating and raises its price target to $49.00 from $43.00.

Melco Resorts & Entertainment (MLCO) — Susquehanna downgrades its rating from Positive to Neutral and lowers its price target to $4.00 from $5.00.

MercadoLibre (MELI) — BTIG Research maintains its Buy rating and lowers its price target to $2,050.00 from $2,150.00.

MercadoLibre (MELI) — Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $2,000.00 from $2,200.00.

MercadoLibre (MELI) — Scotiabank maintains its Sector Outperform rating and lowers its price target to $2,300.00 from $2,800.00.

Meridian (MRBK) — Piper Sandler maintains its Overweight rating and lowers its price target to $20.00 from $24.00.

MGE Energy (MGEE) — Jefferies Financial Group sets a price target of $87.00.

MGM Resorts International (MGM) — Argus maintains its Buy rating and lowers its price target to $40.00 from $55.00.

Mirum Pharmaceuticals (MIRM) — Leerink Partners maintains its Outperform rating and lowers its price target to $140.00 from $154.00.

MKS (MKSI) — Needham & Company LLC maintains its Buy rating and lowers its price target to $300.00 from $390.00.

MNTN (MNTN) — Citizens Jmp downgrades its rating from Market Outperform to Market Perform.

MNTN (MNTN) — Susquehanna maintains its Positive rating and lowers its price target to $12.00 from $20.00.

MNTN Inc. (MNTN) — Citigroup downgrades its rating from Buy to Neutral and lowers its price target to $7.00 from $16.00.

MNTN Inc. (MNTN) — Citizens downgrades its rating from Market Outperform to Market Perform.

MNTN Inc. (MNTN) — Evercore ISI downgrades its rating from Outperform to In-Line with a price target of $7.00.

MNTN Inc. (MNTN) — Raymond James downgrades its rating from Outperform to Market Perform.

Modine Manufacturing (MOD) — Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $178.00 from $275.00.

Modine Manufacturing (MOD) — Oppenheimer maintains its Outperform rating and lowers its price target to $215.00 from $260.00.

Motorola Solutions (MSI) — Barclays maintains its Overweight rating and raises its price target to $598.00 from $529.00.

Motorola Solutions (MSI) — JPMorgan maintains its Overweight rating and raises its price target to $570.00 from $545.00.

Motorola Solutions (MSI) — Piper Sandler maintains its Overweight rating and raises its price target to $533.00 from $531.00.

Motorola Solutions (MSI) — Truist maintains its Buy rating and raises its price target to $555.00 from $550.00.

Motorola Solutions (MSI) — UBS maintains its Buy rating and raises its price target to $570.00 from $520.00.

Mplx (MPLX) — Citigroup maintains its Neutral rating and raises its price target to $56.00 from $55.00.

MYR Group (MYRG) — KeyBanc Capital Markets upgrades its rating from Sector Weight to Overweight with a price target of $361.00.

Myriad Genetics (MYGN) — Leerink Partners maintains its Market Perform rating and raises its price target to $8.00 from $5.00.

Myriad Genetics (MYGN) — TD Cowen maintains its Hold rating and raises its price target to $6.75 from $4.50.

N-able (NABL) — Needham & Company LLC maintains its Buy rating and raises its price target to $6.00 from $4.00.

Navient (NAVI) — Barclays maintains its Underweight rating and lowers its price target to $6.00 from $7.00.

Navient (NAVI) — JPMorgan maintains its Neutral rating and raises its price target to $9.00 from $8.50.

Navient (NAVI) — TD Cowen maintains its Sell rating and lowers its price target to $8.00 from $8.50.

New Era Energy & Digital (NUAI) — Alliance Global Partners initiates coverage with a Buy rating and a price target of $6.00.

New York Times (NYT) — Barclays maintains its Equal Weight rating and raises its price target to $64.00 from $63.00.

NewAmsterdam Pharma (NAMS) — Needham & Company LLC maintains its Buy rating and lowers its price target to $46.00 from $48.00.

Nextpower (NXT) — Cantor Fitzgerald maintains its Overweight rating and raises its price target to $125.00 from $55.00.

NiCE (NICE) — Citizens Jmp maintains its Market Outperform rating and lowers its price target to $158.00 from $170.00.

NiCE (NICE) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $130.00 from $145.00.

Nike (NKE) — Truist downgrades its rating from Hold to Sell with a price target of $29.00.

NNN REIT (NNN) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $43.00 from $42.00.

Nomad Foods (NOMD) — BTIG Research maintains its Buy rating with a price target of $15.00.

NOV (NOV) — Citigroup maintains its Neutral rating and lowers its price target to $20.00 from $21.00.

Nova (NVMI) — Needham & Company LLC maintains its Buy rating and lowers its price target to $420.00 from $570.00.

Nuvation Bio (NUVB) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $17.00 from $20.00.

Ovintiv (OVV) — Truist maintains its Buy rating and raises its price target to $90.00 from $77.00.

Ovintiv (OVV) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $81.00 from $82.00.

Owens Corning (OC) — RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $119.00 from $127.00.

Owens Corning (OC) — Truist maintains its Hold rating and raises its price target to $120.00 from $115.00.

Owens Corning (OC) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $133.00 from $125.00.

Pacific Biosciences of California (PACB) — Barclays maintains its Underweight rating and raises its price target to $2.00 from $1.25.

Pacific Biosciences of California (PACB) — Piper Sandler maintains its Neutral rating and raises its price target to $3.00 from $2.00.

PACS Group (PACS) — Stephens maintains its Overweight rating and raises its price target to $64.00 from $60.00.

PACS Group (PACS) — Truist maintains its Buy rating and raises its price target to $65.00 from $62.00.

PACS Group (PACS) — UBS maintains its Buy rating and raises its price target to $67.00 from $60.00.

PagSeguro Digital (PAGS) — UBS downgrades its rating from Buy to Neutral and lowers its price target to $8.00 from $13.00.

Palomar (PLMR) — Truist sets a price target of $175.00.

Papa John’s International (PZZA) — Stephens maintains its Equal Weight rating with a price target of $19.00.

Pattern Group (PTRN) — JPMorgan maintains its Overweight rating and raises its price target to $29.00 from $27.00.

Pattern Group (PTRN) — Needham & Company LLC maintains its Buy rating and raises its price target to $32.00 from $29.00.

Paycom Software (PAYC) — BTIG Research downgrades its rating from Buy to Neutral.

Paycom Software (PAYC) — JPMorgan maintains its Neutral rating and raises its price target to $265.00 from $264.00.

Paycom Software (PAYC) — KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $297.00 from $295.00.

PayPay (PAYP) — Citigroup maintains its Neutral rating and lowers its price target to $17.00 from $18.00.

The Pennant Group (PNTG) — Oppenheimer maintains its Outperform rating and raises its price target to $50.00 from $47.00.

People Incorporated Common Stock (PPLI) — UBS maintains its Neutral rating and lowers its price target to $45.00 from $56.00.

Performance Food Group (PFGC) — Sanford C. Bernstein maintains its Outperform rating and raises its price target to $135.00 from $130.00.

Performance Food Group (PFGC) — UBS maintains its Buy rating and raises its price target to $133.00 from $130.00.

Pfizer (PFE) — Guggenheim maintains its Buy rating and raises its price target to $33.00 from $31.00.

Phillips Edison & Company, Inc. (PECO) — JPMorgan maintains its Neutral rating and raises its price target to $43.00 from $41.00.

Planet Fitness (PLNT) — Raymond James maintains its Strong-Buy rating with a price target of $72.00.

Power Integrations (POWI) — Needham & Company LLC maintains its Buy rating and lowers its price target to $65.00 from $80.00.

Power Integrations (POWI) — Stifel sets a price target of $62.00.

Power Integrations (POWI) — Susquehanna maintains its Positive rating and lowers its price target to $55.00 from $70.00.

Power Integrations (POWI) — Williams Trading sets a price target of $65.00.

Precigen (PGEN) — Citizens Jmp maintains its Market Outperform rating and raises its price target to $12.00 from $11.00.

Precigen (PGEN) — Raymond James sets a price target of $12.00.

Primoris Services (PRIM) — Needham & Company LLC maintains its Buy rating and lowers its price target to $110.00 from $172.00.

Primoris Services (PRIM) — Oppenheimer maintains its Outperform rating and lowers its price target to $115.00 from $135.00.

PROCEPT BioRobotics (PRCT) — Leerink Partners maintains its Market Perform rating and raises its price target to $22.00 from $20.00.

PROCEPT BioRobotics (PRCT) — UBS maintains its Neutral rating and raises its price target to $21.00 from $20.00.

Procore Technologies (PCOR) — Barclays maintains its Overweight rating and raises its price target to $85.00 from $62.00.

Procore Technologies (PCOR) — BTIG Research maintains its Buy rating and raises its price target to $90.00 from $66.00.

Procore Technologies (PCOR) — Cantor Fitzgerald maintains its Overweight rating and raises its price target to $90.00 from $70.00.

Procore Technologies (PCOR) — Citizens Jmp maintains its Market Outperform rating and raises its price target to $91.00 from $77.00.

Procore Technologies (PCOR) — Goldman Sachs maintains its Buy rating and raises its price target to $90.00 from $70.00.

Procore Technologies (PCOR) — Guggenheim maintains its Buy rating and raises its price target to $85.00 from $68.00.

Procore Technologies (PCOR) — Loop Capital upgrades its rating from Hold to Buy with a price target of $93.00.

Procore Technologies (PCOR) — Piper Sandler maintains its Overweight rating and raises its price target to $90.00 from $68.00.

Procore Technologies (PCOR) — Truist sets a price target of $91.00.

Procore Technologies (PCOR) — UBS maintains its Buy rating and raises its price target to $95.00 from $80.00.

Progyny (PGNY) — Cantor Fitzgerald maintains its Overweight rating and raises its price target to $35.00 from $31.00.

Progyny (PGNY) — Citizens Jmp maintains its Market Outperform rating and raises its price target to $38.00 from $33.00.

Progyny (PGNY) — Leerink Partners maintains its Outperform rating and raises its price target to $38.00 from $37.00.

Progyny (PGNY) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $38.00 from $37.00.

Prudential Financial (PRU) — Piper Sandler maintains its Neutral rating and raises its price target to $133.00 from $120.00.

PureCycle Technologies (PCT) — Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $8.00 from $12.00.

Pursuit Attractions and Hospitality (PRSU) — Oppenheimer maintains its Outperform rating and raises its price target to $65.00 from $58.00.

Pyxis Oncology (PYXS) — Stifel sets a price target of $5.00.

Qualcomm (QCOM) — Barclays maintains its Underweight rating and lowers its price target to $150.00 from $180.00.

Qualcomm (QCOM) — JPMorgan maintains its Neutral rating and lowers its price target to $200.00 from $215.00.

Qualcomm (QCOM) — Robert W. Baird sets a price target of $320.00.

Qualcomm (QCOM) — Rosenblatt Securities maintains its Buy rating and lowers its price target to $205.00 from $235.00.

Qualcomm (QCOM) — Susquehanna maintains its Neutral rating and lowers its price target to $165.00 from $185.00.

Qualcomm (QCOM) — TD Cowen maintains its Buy rating and lowers its price target to $185.00 from $200.00.

Qualcomm (QCOM) — UBS maintains its Neutral rating and lowers its price target to $180.00 from $185.00.

Ralliant (RAL) — Citigroup maintains its Buy rating and raises its price target to $88.00 from $85.00.

Ralliant (RAL) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $73.00 from $72.00.

Ralliant (RAL) — Truist maintains its Buy rating and raises its price target to $88.00 from $82.00.

Rapid7 (RPD) — Barclays maintains its Underweight rating and raises its price target to $14.00 from $12.00.

Rapid7 (RPD) — Citigroup maintains its Neutral rating and raises its price target to $16.00 from $13.00.

Rapid7 (RPD) — Piper Sandler maintains its Neutral rating and raises its price target to $20.00 from $12.00.

Rapid7 (RPD) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $16.00 from $12.00.

Rapid7 (RPD) — Scotiabank maintains its Sector Perform rating and raises its price target to $14.50 from $10.15.

Rapid7 (RPD) — Truist maintains its Hold rating and raises its price target to $15.00 from $10.00.

Rapid7 (RPD) — UBS maintains its Neutral rating and raises its price target to $19.00 from $12.00.

Rapport Therapeutics (RAPP) — Guggenheim maintains its Buy rating and lowers its price target to $66.00 from $70.00.

Rapport Therapeutics (RAPP) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $47.00 from $50.00.

Real REMAX Group (REAX) — BTIG Research maintains its Buy rating and lowers its price target to $25.00 from $35.00.

Realty Income (O) — Cantor Fitzgerald maintains its Neutral rating and lowers its price target to $63.00 from $68.00.

Red Rock Resorts (RRR) — Citigroup maintains its Buy rating and lowers its price target to $65.00 from $69.00.

Red Rock Resorts (RRR) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $65.00 from $78.00.

Red Violet (RDVT) — Needham & Company LLC maintains its Buy rating and raises its price target to $100.00 from $90.00.

Revolution Medicines (RVMD) — Guggenheim maintains its Buy rating and raises its price target to $298.00 from $275.00.

Revolution Medicines (RVMD) — Piper Sandler maintains its Overweight rating and raises its price target to $222.00 from $210.00.

Revolution Medicines (RVMD) — RBC Capital Markets maintains its Outperform rating and raises its price target to $321.00 from $260.00.

Revolution Medicines (RVMD) — TD Cowen maintains its Buy rating and raises its price target to $270.00 from $250.00.

Revolution Medicines (RVMD) — Truist maintains its Buy rating and raises its price target to $261.00 from $241.00.

Reynolds Consumer Products (REYN) — UBS maintains its Neutral rating and raises its price target to $27.00 from $24.00.

Rhythm Pharmaceuticals (RYTM) — Guggenheim maintains its Buy rating and raises its price target to $147.00 from $143.00.

Ridgepost Capital (RPC) — Barclays maintains its Overweight rating and raises its price target to $12.00 from $11.00.

Ridgepost Capital (RPC) — JPMorgan maintains its Overweight rating and raises its price target to $15.00 from $14.00.

Ridgepost Capital (RPC) — Oppenheimer maintains its Outperform rating and lowers its price target to $14.00 from $15.00.

Root (ROOT) — Keefe, Bruyette & Woods maintains its Outperform rating and lowers its price target to $70.00 from $75.00.

Root (ROOT) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $53.00 from $47.00.

Royalty Pharma (RPRX) — Citigroup maintains its Buy rating and raises its price target to $78.00 from $70.00.

Schrodinger (SDGR) — TD Cowen maintains its Buy rating and raises its price target to $36.00 from $31.00.

Scotts Miracle-Gro (SMG) — JPMorgan maintains its Neutral rating and lowers its price target to $67.00 from $70.00.

Scotts Miracle-Gro (SMG) — UBS maintains its Buy rating and raises its price target to $77.00 from $70.00.

Scotts Miracle-Gro (SMG) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $76.00 from $71.00.

Seacoast Banking Corporation of Florida (SBCF) — Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $38.00 from $37.00.

Seaport Therapeutics (SPTX) — JPMorgan maintains its Overweight rating and raises its price target to $41.00 from $40.00.

Sezzle (SEZL) — Needham & Company LLC maintains its Buy rating and raises its price target to $220.00 from $172.00.

Sezzle (SEZL) — TD Cowen maintains its Buy rating and raises its price target to $200.00 from $160.00.

SharkNinja (SN) — BTIG Research maintains its Buy rating and raises its price target to $250.00 from $245.00.

SharkNinja (SN) — JPMorgan maintains its Overweight rating and raises its price target to $243.00 from $223.00.

Shoals Technologies Group (SHLS) — Cantor Fitzgerald maintains its Overweight rating and raises its price target to $12.00 from $11.00.

Shopify (SHOP) — Argus maintains its Buy rating with a price target of $180.00.

Sight Sciences (SGHT) — Piper Sandler maintains its Overweight rating and raises its price target to $12.00 from $9.00.

Silvaco Group (SVCO) — TD Cowen maintains its Buy rating and lowers its price target to $12.00 from $15.00.

SiTime (SITM) — Needham & Company LLC maintains its Buy rating and lowers its price target to $600.00 from $900.00.

Six Flags Entertainment (FUN) — Stifel sets a price target of $15.00.

Skyworks (SWKS) — Barclays downgrades its rating from Overweight to Equal Weight and raises its price target to $79.00 from $70.00.

SM Energy (SM) — Susquehanna sets a price target of $33.00.

SM Energy (SM) — Truist maintains its Buy rating and lowers its price target to $47.00 from $48.00.

SM Energy (SM) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $46.00 from $47.00.

Snap (SNAP) — Barclays maintains its Overweight rating and lowers its price target to $8.00 from $16.00.

Snap (SNAP) — Cantor Fitzgerald maintains its Neutral rating and lowers its price target to $5.00 from $6.00.

Snap (SNAP) — JPMorgan maintains its Underweight rating and lowers its price target to $5.00 from $6.00.

Snap (SNAP) — Raymond James maintains its Outperform rating with a price target of $7.00.

SolarEdge Technologies (SEDG) — Citigroup maintains its Sell rating and lowers its price target to $24.00 from $30.00.

SolarEdge Technologies (SEDG) — Goldman Sachs maintains its Sell rating and lowers its price target to $25.00 from $29.00.

SolarEdge Technologies (SEDG) — JPMorgan maintains its Neutral rating and lowers its price target to $31.00 from $38.00.

SolarEdge Technologies (SEDG) — Susquehanna maintains its Neutral rating and lowers its price target to $31.00 from $32.00.

Sony (SONY) — Sanford C. Bernstein maintains its Market Perform rating with a price target of $26.00.

South Bow (SOBO) — Barclays maintains its Underweight rating and raises its price target to $34.00 from $33.00.

SpaceX (SPCX) — China Renaissance initiates coverage with a Buy rating and a price target of $194.20.

Sprout Social (SPT) — Barclays maintains its Overweight rating and raises its price target to $14.00 from $12.00.

Sprouts Farmers Market (SFM) — Northcoast downgrades its rating from Buy to Neutral.

Sprouts Farmers Market (SFM) — Northcoast Research downgrades its rating from Buy to Neutral.

STAAR Surgical (STAA) — UBS sets a price target of $34.00.

Stanley Black & Decker (SWK) — Citigroup maintains its Buy rating and raises its price target to $140.00 from $107.00.

Stanley Black & Decker (SWK) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $115.00 from $90.00.

Steven Madden (SHOO) — Needham & Company LLC maintains its Buy rating and lowers its price target to $45.00 from $52.00.

StoneCo (STNE) — UBS downgrades its rating from Buy to Neutral and lowers its price target to $8.50 from $15.00.

Sun Life (SLF) — National Bank Financial downgrades its rating from Outperform to Sector Perform.

Sunrun (RUN) — Citigroup maintains its Buy rating and lowers its price target to $13.00 from $14.00.

Sunrun (RUN) — JPMorgan maintains its Overweight rating and lowers its price target to $11.00 from $12.00.

Sysco (SYY) — Citigroup maintains its Neutral rating and lowers its price target to $84.00 from $87.00.

Taboola (TBLA) — Rosenblatt downgrades its rating from Buy to Neutral with a price target of $2.80.

Taboola.com (TBLA) — Needham & Company LLC maintains its Buy rating and lowers its price target to $4.00 from $5.50.

Taboola.com (TBLA) — Rosenblatt Securities downgrades its rating from Buy to Neutral with a price target of $2.80.

Targa Resources (TRGP) — Raymond James sets a price target of $344.00.

Tarsus Pharmaceuticals (TARS) — Guggenheim maintains its Buy rating and raises its price target to $97.00 from $89.00.

TaskUs (TASK) — Goldman Sachs maintains its Sell rating and raises its price target to $8.00 from $7.00.

Teads (TEAD) — Needham & Company LLC maintains its Buy rating and lowers its price target to $0.40 from $1.00.

Teladoc Health (TDOC) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $8.00 from $6.00.

Tennant (TNC) — Subscribe to MarketBeat All Access to unlock brokerage rankings upgrades its rating from Hold to Buy and raises its price target to $85.00 from $77.00.

Tennant (TNC) — UBS sets a price target of $85.00.

Ternium (TX) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $52.00 from $56.00.

Teva Pharmaceutical Industries (TEVA) — Leerink Partners maintains its Outperform rating and raises its price target to $52.00 from $45.00.

thredUP (TDUP) — Northland Capital downgrades its rating from Outperform to Market Perform with a price target of $2.00.

ThredUp (TDUP) — Northland Securities downgrades its rating from Outperform to Market Perform with a price target of $2.00.

ThredUp (TDUP) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $3.00 from $8.00.

thredUP (TDUP) — William Blair downgrades its rating from Outperform to Market Perform.

Timken (TKR) — Citigroup maintains its Buy rating and lowers its price target to $125.00 from $140.00.

Timken (TKR) — Goldman Sachs maintains its Neutral rating with a price target of $126.00.

TKO Group (TKO) — Guggenheim maintains its Buy rating and raises its price target to $240.00 from $228.00.

TKO Group (TKO) — Susquehanna maintains its Positive rating and lowers its price target to $223.00 from $224.00.

Traeger (COOK) — Telsey Advisory Group sets a price target of $58.00.

Travere Therapeutics (TVTX) — Leerink Partners maintains its Outperform rating and lowers its price target to $67.00 from $78.00.

Trex (TREX) — Bank of America upgrades its rating from Underperform to Buy and raises its price target to $65.00 from $46.00.

Trex (TREX) — Barclays maintains its Underweight rating and raises its price target to $46.00 from $42.00.

Trex (TREX) — Citigroup maintains its Neutral rating and raises its price target to $59.00 from $52.00.

Trex (TREX) — Truist maintains its Buy rating and raises its price target to $75.00 from $60.00.

Trimble (TRMB) — JPMorgan maintains its Overweight rating and lowers its price target to $73.00 from $75.00.

Trimble (TRMB) — Oppenheimer maintains its Outperform rating and lowers its price target to $73.00 from $80.00.

Trimble (TRMB) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $60.00 from $61.00.

Trinity Capital (TRIN) — Keefe, Bruyette & Woods maintains its Market Perform rating and raises its price target to $18.00 from $16.50.

Trinity Capital (TRIN) — Wells Fargo & Company maintains its Underweight rating and raises its price target to $16.00 from $15.00.

Trinity Industries (TRN) — Susquehanna maintains its Neutral rating and raises its price target to $34.00 from $32.00.

TriplePoint Venture Growth BDC (TPVG) — Keefe, Bruyette & Woods maintains its Market Perform rating and lowers its price target to $5.00 from $5.50.

Trivago N.V. ADS (TRVG) — Susquehanna maintains its Neutral rating and lowers its price target to $4.00 from $5.50.

Tutor Perini (TPC) — UBS maintains its Buy rating and raises its price target to $107.00 from $105.00.

TWFG (TWFG) — Keefe, Bruyette & Woods maintains its Market Perform rating and raises its price target to $30.00 from $28.00.

TWFG (TWFG) — Piper Sandler maintains its Overweight rating and raises its price target to $34.00 from $31.00.

Uber Technologies (UBER) — Barclays maintains its Overweight rating and lowers its price target to $100.00 from $106.00.

Uber Technologies (UBER) — Canaccord Genuity Group maintains its Hold rating and lowers its price target to $70.00 from $72.00.

Uber Technologies (UBER) — Cantor Fitzgerald maintains its Overweight rating with a price target of $90.00.

Uber Technologies (UBER) — Goldman Sachs maintains its Buy rating and lowers its price target to $110.00 from $115.00.

Uber Technologies (UBER) — Guggenheim maintains its Buy rating with a price target of $125.00.

Uber Technologies (UBER) — KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $95.00 from $105.00.

Uber Technologies (UBER) — Needham & Company LLC maintains its Buy rating and lowers its price target to $100.00 from $109.00.

Uber Technologies (UBER) — Rosenblatt Securities maintains its Buy rating and lowers its price target to $95.00 from $100.00.

Uber Technologies (UBER) — Sanford C. Bernstein maintains its Outperform rating and lowers its price target to $90.00 from $95.00.

Uber Technologies (UBER) — Wedbush maintains its Outperform rating with a price target of $91.00.

Uber Technologies (UBER) — Wells Fargo & Company maintains its Overweight rating and lowers its price target to $87.00 from $92.00.

Ultragenyx Pharmaceutical (RARE) — Barclays maintains its Overweight rating and lowers its price target to $32.00 from $35.00.

Ultragenyx Pharmaceutical (RARE) — Citigroup maintains its Buy rating and lowers its price target to $22.00 from $32.00.

Union Pacific (UNP) — Robert W. Baird downgrades its rating from Outperform to Neutral and lowers its price target to $310.00 from $344.00.

United Fire Group (UFCS) — Piper Sandler maintains its Overweight rating and lowers its price target to $58.00 from $60.00.

United Therapeutics (UTHR) — RBC Capital Markets maintains its Outperform rating and raises its price target to $725.00 from $697.00.

United Therapeutics (UTHR) — TD Cowen maintains its Buy rating and raises its price target to $700.00 from $675.00.

United Therapeutics (UTHR) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $703.00 from $700.00.

Unity Software (U) — BTIG Research maintains its Buy rating and raises its price target to $60.00 from $53.00.

Unity Software (U) — Raymond James maintains its Outperform rating with a price target of $60.00.

Unum Group (UNM) — Keefe, Bruyette & Woods maintains its Outperform rating and lowers its price target to $97.00 from $108.00.

Unum Group (UNM) — Truist maintains its Buy rating and lowers its price target to $85.00 from $96.00.

Upland Software (UPLD) — Needham & Company LLC maintains its Buy rating and lowers its price target to $6.00 from $10.00.

Urogen Pharma (URGN) — Guggenheim maintains its Buy rating and lowers its price target to $56.00 from $58.00.

Urogen Pharma (URGN) — Oppenheimer sets a price target of $60.00.

US Foods (USFD) — TD Cowen maintains its Buy rating and raises its price target to $125.00 from $119.00.

V.F. (VFC) — Barclays maintains its Overweight rating and raises its price target to $28.00 from $24.00.

Varonis Systems (VRNS) — Susquehanna downgrades its rating from Positive to Neutral and lowers its price target to $49.75 from $55.00.

Veracyte (VCYT) — Leerink Partners downgrades its rating from Outperform to Market Perform and lowers its price target to $35.00 from $55.00.

Veracyte (VCYT) — Needham & Company LLC maintains its Buy rating and lowers its price target to $46.00 from $69.00.

Versigent (VGNT) — BNP Paribas Exane maintains its Outperform rating and lowers its price target to $54.00 from $55.00.

Versigent (VGNT) — RBC Capital Markets maintains its Outperform rating and lowers its price target to $52.00 from $53.00.

Versigent (VGNT) — TD Cowen maintains its Buy rating and raises its price target to $59.00 from $58.00.

Vertex (VERX) — DA Davidson sets a price target of $16.00.

Vertex (VERX) — Needham & Company LLC maintains its Buy rating and raises its price target to $30.00 from $20.00.

Vertex (VERX) — Piper Sandler maintains its Neutral rating and raises its price target to $20.00 from $16.00.

Viavi Solutions (VIAV) — Needham & Company LLC maintains its Buy rating and lowers its price target to $53.00 from $60.00.

VICI Properties (VICI) — Citigroup maintains its Buy rating and lowers its price target to $30.00 from $36.00.

Vir Biotechnology (VIR) — Needham & Company LLC maintains its Buy rating and raises its price target to $20.00 from $18.00.

Viridian Therapeutics (VRDN) — HC Wainwright maintains its Buy rating and raises its price target to $40.00 from $22.00.

Viridian Therapeutics (VRDN) — Leerink Partners maintains its Outperform rating and raises its price target to $54.00 from $50.00.

Viridian Therapeutics (VRDN) — RBC Capital Markets maintains its Outperform rating and raises its price target to $41.00 from $38.00.

Viridian Therapeutics (VRDN) — Truist maintains its Buy rating and raises its price target to $42.00 from $39.00.

Viridian Therapeutics (VRDN) — Wedbush maintains its Outperform rating and raises its price target to $42.00 from $41.00.

Viridian Therapeutics (VRDN) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $34.00 from $31.00.

Visa (V) — Truist maintains its Buy rating and raises its price target to $470.00 from $443.00.

Vishay Intertechnology (VSH) — Needham & Company LLC maintains its Buy rating and lowers its price target to $38.00 from $45.00.

Vishay Intertechnology (VSH) — Williams Trading sets a price target of $38.00.

Vistra (VST) — BMO Capital Markets maintains its Outperform rating and lowers its price target to $188.00 from $210.00.

W.W. Grainger (GWW) — Oppenheimer maintains its Outperform rating and raises its price target to $1,645.00 from $1,375.00.

W.W. Grainger (GWW) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $1,582.00 from $1,427.00.

W.W. Grainger (GWW) — Sanford C. Bernstein maintains its Market Perform rating with a price target of $1,400.00.

W.W. Grainger (GWW) — Stephens maintains its Equal Weight rating and raises its price target to $1,380.00 from $1,355.00.

Wayfair (W) — BNP Paribas Exane maintains its Neutral rating and raises its price target to $134.00 from $108.00.

Wayfair (W) — Needham & Company LLC maintains its Buy rating and raises its price target to $145.00 from $133.00.

Wayfair (W) — RBC Capital Markets maintains its Sector Perform rating and raises its price target to $128.00 from $96.00.

Wayfair (W) — Sanford C. Bernstein maintains its Outperform rating and raises its price target to $140.00 from $125.00.

Wayfair (W) — TD Cowen maintains its Hold rating and raises its price target to $114.00 from $110.00.

Wayfair (W) — UBS maintains its Buy rating and raises its price target to $165.00 from $156.00.

Wayfair (W) — Wedbush maintains its Neutral rating and raises its price target to $138.00 from $125.00.

Wayfair (W) — Wells Fargo & Company maintains its Overweight rating and raises its price target to $140.00 from $130.00.

Western Union (WU) — UBS maintains its Neutral rating and raises its price target to $6.50 from $6.25.

Willis Towers Watson Public (WTW) — Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $397.00 from $360.00.

Wolfspeed (WOLF) — TD Cowen maintains its Hold rating and lowers its price target to $23.00 from $25.00.

Xencor (XNCR) — Cantor Fitzgerald maintains its Overweight rating with a price target of $70.00.

Yum! Brands (YUM) — Guggenheim maintains its Buy rating and raises its price target to $180.00 from $155.00.

Zillow Group (ZG) — Cantor Fitzgerald maintains its Neutral rating and lowers its price target to $26.00 from $32.00.

Zillow Group (ZG) — Citizens Jmp maintains its Market Outperform rating and lowers its price target to $40.00 from $46.00.

Zillow Group (ZG) — Evercore ISI maintains its Reduce rating with a price target of $35.00.

Zillow Group (ZG) — Piper Sandler maintains its Overweight rating and lowers its price target to $39.00 from $46.00.

Zillow Group (ZG) — Sanford C. Bernstein maintains its Market Perform rating and lowers its price target to $34.00 from $38.00.

Zillow Group (ZG) — Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $30.00 from $31.00.

Zimmer Biomet (ZBH) — Citigroup maintains its Neutral rating and raises its price target to $117.00 from $99.00.

Zimmer Biomet (ZBH) — JPMorgan maintains its Neutral rating and raises its price target to $120.00 from $117.00.

Zimmer Biomet (ZBH) — RBC Capital Markets maintains its Outperform rating and raises its price target to $125.00 from $110.00.

Zimmer Biomet (ZBH) — Sanford C. Bernstein maintains its Market Perform rating and raises its price target to $107.00 from $93.00.

Zimmer Biomet (ZBH) — Truist sets a price target of $114.00.

Zimmer Biomet (ZBH) — UBS maintains its Buy rating and raises its price target to $130.00 from $120.00.

Zimmer Biomet (ZBH) — Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $113.00 from $103.00.

ZoomInfo (GTM) — Piper Sandler upgrades its rating from Underweight to Neutral and raises its price target to $4.00 from $3.00.

ZoomInfo Technologies (GTM) — Needham & Company LLC maintains its Buy rating and lowers its price target to $8.00 from $15.00.

ZoomInfo Technologies (GTM) — RBC Capital Markets maintains its Underperform rating and raises its price target to $3.50 from $3.00.

Keep researching

Related research

Mar 6, 2025

How Trump’s Tariffs Could Shake Up Magna International’s Auto Parts Business

Oct 24, 2023

STA Research (Rank#25) Maintained “Hold” Rating on Starbucks, $110 target (SBUX:NSD)

Oct 23, 2023

Bank of Canada Looks to Pause rates as Recession Looms

Nov 5, 2026

American Analyst Updates: Nov 4th, 2026

Nov 3, 2026

American Analyst Updates: Nov 3rd, 2026

Nov 3, 2026

American Analyst Updates: Nov 2nd, 2026

A monthly perspective in your inbox.
Five research sections in the STA Research Professional Newsletter.

Read a sample →